CLOs on the Move

Zentaris

www.zentaris.com

 
Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zentaris.com
  • 315 Sigma Drive
    Summerville, QC CAN 29486
  • Phone: 843.900.3223

Executives

Name Title Contact Details

Similar Companies

Caron Products and Services

Caron Products is a provider of incubators & chambers for cell growth and product environmental testing in biological research, scale-up culture, and drug and biological QA/QC testing. Caron`s products are integral to workflows ranging from cell & gene therapy to medical device manufacturing. Caron`s expanding resources, with manufacturing facilities in both the USA and Europe, and a worldwide network of sales and service personnel aligns with the needs of the global biomedical industry.

SOLESIS

Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.

Infinant Health

Infinant Health is a life sciences company that is committed to changing the trajectory of human health, one baby at a time, through their deep understanding of infant nutrition and the gut microbiome.

Recursion Pharmaceuticals

Recursion Pharmaceuticals has developed a powerful drug discovery platform involving millions of rapid, automated experiments and analysis to discover new therapeutics.